Sequential treatment with afatinib and osimertinib in real-world patients with EGFR mutation-positive advanced NSCLC: the GioTag study

Authors :: Hochmair, M.
Cufer, T.
Morabito, A.
Hao, D.
Ta Yang, C.
Soo, R.
Yang, J.
Gucalp, R.
Halmos, B.
Wang, L.
Golembesky, A.
Märten, A.
O?Byrne, K.
Hochmair, M.
Cufer, T.
Morabito, A.
Hao, D.
Ta Yang, C.
Soo, R.
Yang, J.
Gucalp, R.
Halmos, B.
Wang, L.
Golembesky, A.
Märten, A.
O?Byrne, K.
Source :: 17th Annual British Thoracic Oncology Group Conference (BTOG 2019)
Publication Year :: 2019
Abstract: The GioTag study aimed to assess outcomes in real-world patients who received first-line afatinib followed by osimertinb.

Database :: OAIster
Journal :: 17th Annual British Thoracic Oncology Group Conference (BTOG 2019)
Notes :: application/pdf
Publication Type :: Electronic Resource
Accession number :: edsoai.on1129474061
Document Type :: Electronic Resource

Tools